These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Structure-activity relationships of glucagon-like peptide-1(7-36)amide: insulinotropic activities in perfused rat pancreases, and receptor binding and cyclic AMP production in RINm5F cells. Watanabe Y; Kawai K; Ohashi S; Yokota C; Suzuki S; Yamashita K J Endocrinol; 1994 Jan; 140(1):45-52. PubMed ID: 8138751 [TBL] [Abstract][Full Text] [Related]
3. Comparison of the effects of various C-terminal and N-terminal fragment peptides of glucagon-like peptide-1 on insulin and glucagon release from the isolated perfused rat pancreas. Suzuki S; Kawai K; Ohashi S; Mukai H; Yamashita K Endocrinology; 1989 Dec; 125(6):3109-14. PubMed ID: 2684616 [TBL] [Abstract][Full Text] [Related]
4. Interaction of glucagon-like peptide-1(7-36)amide and somatostatin-14 in RINm5F cells and in the perfused rat pancreas. Göke R; Fehmann HC; Richter G; Trautmann M; Göke B Pancreas; 1989; 4(6):668-73. PubMed ID: 2573056 [TBL] [Abstract][Full Text] [Related]
5. Glucagonostatic and insulinotropic action of glucagonlike peptide I-(7-36)-amide. Komatsu R; Matsuyama T; Namba M; Watanabe N; Itoh H; Kono N; Tarui S Diabetes; 1989 Jul; 38(7):902-5. PubMed ID: 2661287 [TBL] [Abstract][Full Text] [Related]
7. Effects of glucagon-like peptide 1 (7-36) amide and glucagon on amylin release from perfused rat pancreas. Inoue K; Hisatomi A; Umeda F; Nawata H Horm Metab Res; 1991 Sep; 23(9):407-9. PubMed ID: 1743611 [TBL] [Abstract][Full Text] [Related]
8. Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas. Mojsov S; Weir GC; Habener JF J Clin Invest; 1987 Feb; 79(2):616-9. PubMed ID: 3543057 [TBL] [Abstract][Full Text] [Related]
9. Effect of glucagon-like peptide-1 on insulin secretion. Shima K; Hirota M; Ohboshi C Regul Pept; 1988 Aug; 22(3):245-52. PubMed ID: 3051138 [TBL] [Abstract][Full Text] [Related]
11. Comparison of the effects of glucagon-like peptide-1-(1-37) and -(7-37) and glucagon on islet hormone release from isolated perfused canine and rat pancreases. Kawai K; Suzuki S; Ohashi S; Mukai H; Ohmori H; Murayama Y; Yamashita K Endocrinology; 1989 Apr; 124(4):1768-73. PubMed ID: 2564338 [TBL] [Abstract][Full Text] [Related]
12. Glucagon-like peptide-1 improves insulin and proinsulin binding on RINm5F cells and human monocytes. Ebinger M; Jehle DR; Fussgaenger RD; Fehmann HC; Jehle PM Am J Physiol Endocrinol Metab; 2000 Jul; 279(1):E88-94. PubMed ID: 10893327 [TBL] [Abstract][Full Text] [Related]
13. Glucagonlike peptide-1(7-36)amide suppresses glucagon secretion and decreases cyclic AMP concentration in cultured In-R1-G9 cells. Matsumura T; Itoh H; Watanabe N; Oda Y; Tanaka M; Namba M; Kono N; Matsuyama T; Komatsu R; Matsuzawa Y Biochem Biophys Res Commun; 1992 Jul; 186(1):503-8. PubMed ID: 1378730 [TBL] [Abstract][Full Text] [Related]
14. Multisite regulation of insulin secretion by cAMP-increasing agonists: evidence that glucagon-like peptide 1 and glucagon act via distinct receptors. Gromada J; Ding WG; Barg S; Renström E; Rorsman P Pflugers Arch; 1997 Sep; 434(5):515-24. PubMed ID: 9242714 [TBL] [Abstract][Full Text] [Related]
15. Glucagon-like peptide-1 (7-36 amide): a potent glucagonostatic and insulinotropic hormone. Matsuyama T; Komatsu R; Namba M; Watanabe N; Itoh H; Tarui S Diabetes Res Clin Pract; 1988 Oct; 5(4):281-4. PubMed ID: 3069410 [TBL] [Abstract][Full Text] [Related]
16. Neuropeptide Y expression and regulation in a differentiated rat insulin-secreting cell line. Waeber G; Thompson N; Waeber B; Brunner HR; Nicod P; Grouzmann E Endocrinology; 1993 Sep; 133(3):1061-7. PubMed ID: 8396008 [TBL] [Abstract][Full Text] [Related]
17. Stimulatory effects of glucagon-like peptides on human insulinoma cells and insulin-releasing clonal RINm5F cells. Flatt PR; Shiber O; Hampton SM; Marks V Diabetes Res; 1990 Feb; 13(2):55-9. PubMed ID: 1965428 [TBL] [Abstract][Full Text] [Related]
18. N-terminal acetylation protects glucagon-like peptide GLP-1-(7-34)-amide from DPP-IV-mediated degradation retaining cAMP- and insulin-releasing capacity. John H; Maronde E; Forssmann WG; Meyer M; Adermann K Eur J Med Res; 2008 Feb; 13(2):73-8. PubMed ID: 18424366 [TBL] [Abstract][Full Text] [Related]